Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
limosilactobacillus reuteri AMBV339 + Humiome B2
- Development stage
- Unknown
- Lead developer
- DSM-Firmenich
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Limosilactobacillus reuteri AMBV339 + Humiome B2 is an investigational combination product comprising a live biotherapeutic probiotic and a targeted vitamin formulation. The probiotic component is Limosilactobacillus reuteri AMBV339, a human-derived strain selected for its ability to overproduce riboflavin (vitamin B2). The second component, Humiome B2, is a colon-targeted riboflavin supplement (10 mg). This combination is designed to enhance the availability of riboflavin in the distal gut and vaginal environments, where it acts as a metabolic mediator to promote a healthy microbiome. The product is currently being studied in the VIAB2L clinical trial (NCT06425081) to evaluate its effects on the intestinal and vaginal microbiome and metabolome in healthy adult women.
- Other names
- limosilactobacillus reuteri AMBV339 + Humiome B2L. reuteri AMBV339 + riboflavin
Beyond the preview
Go deeper on limosilactobacillus reuteri AMBV339 + Humiome B2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on limosilactobacillus reuteri AMBV339 + Humiome B2.